Report #2889538

Overview

Sex

Female

Age

Age unknown

State

—

Recovered

Recovered

Vaccinated

Jul 28, 2025

Onset

Jul 31, 2025

Days to onset

3

Hospital days

—

Symptoms (1)

Symptom narrative

patient developed fever which reportedly "worsened with Vivotif; Case reference number US-BN-2025-001459 is a spontaneous case initially received from a nurse via Bavarian Nordic (reference number: BN_2025_00258) on 26-Aug-2025 and concerns a 24-years-old female patient. The patient's medical history and concomitant medication details were not provided The patient's current condition included fever. On 28-Jul-2025, the patient received *a dose* of Vivotif vaccine (batch number: 3004333, expiration date 31-Jul-2026) orally for indication typhoid fever prevention. On the same day, the patient received a dose of the co-suspect vaccines IXCHIQ (chikungunya virus vaccine live (vero))(batch number: unknown), at unknown dose, route or site of administration for unknown indication, Vaxchora (batch number: unknown), at unknown dose, route or site of administration for unknown indication and YF (yellow fever vaccine live (17d-204), batch number: unknown), at unknown dose, route or site of administration for unknown indication all at an unknown dose, route, or site for administration for an unknown indication. On 31-Jul-2028, four days after the vaccination with Vivotif and Vaxchora, the patient developed a moderate fever, which reportedly worsened with Vivotif until day seven. On 09-Aug-2025, the patient recovered from the event of 'fever'. The reporter assessed the event of 'fever' as non-serious and probably related to Vivotif. The reporter did not provide a causality assessment for the event 'fever' for the product of Vaxchora. This case is linked with case US-BN-2025-001458 (the same reporter). Additional information was received from Bavarian Nordic on 26-Aug-2025 and included: the country of occurrence. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow-up information received from the nurse on 10-Nov-2025. New information included administration details for Vivotif, co-suspect vaccines (Vaxchora and YF) and event details. Follow-up information received from the nurse on 08-Dec-2025. New information received and it was confirmed that the patient did not take all four doses on same day.; Reporter's Comments: A 24-year-old female patient received a dose of Vivotif vaccine for indication typhoid fever prevention. On the same day, the patient received a dose of the co-suspect vaccines IXCHIQ, Vaxchora and YF. Four days after the vaccination with Vivotif and Vaxchora, the patient experienced non-serious event of pyrexia. Pyrexia is listed for Vivotif and expected. The patient's medical history and concomitant medication details were not provided, and current condition included fever. The patient recovered from the event. The patient ‘s vaccination with co-suspect vaccines and current condition confounded the causality. However, considering compatible temporal relationship and known vaccines safety profile, the reported event has been considered as related to Vivotif and Vaxchora vaccine. This case is considered as non-serious. For regulatory reporting purposes, this case is considered related.; Sender's Comments: A 24-year-old female patient received a dose of Vivotif vaccine for indication typhoid fever prevention. On the same day, the patient received a dose of the co-suspect vaccines IXCHIQ, Vaxchora and YF. Four days after the vaccination with Vivotif and Vaxchora, the patient experienced non-serious event of pyrexia. Pyrexia is listed for Vivotif and expected. The patient's medical history and concomitant medication details were not provided, and current condition included fever. The patient recovered from the event. The patient ‘s vaccination with co-suspect vaccines and current condition confounded the causality. However, considering compatible temporal relationship and known vaccines safety profile, the reported event has been considered as related to Vivotif and Vaxchora vaccine. This case is considered as non-serious. For regulatory reporting purposes, this case is considered related.

Medical history

Medical History/Concurrent Conditions: Fever